65 results about "Cholesterylester transfer protein" patented technology

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

The present invention relates to a compound of the general formula (1):

wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted heterocyclic group, and the like; R¹ is an optionally substituted alkyl group, wherein the alkyl group further may optionally be substituted by an optionally substituted homocyclic group, and the like; and R² is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

The present invention relates to a compound of the general formula (1):

wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted phenyl group, and the like; R¹ is an optionally substituted alkyl group, and the like; and R² is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.

The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such as a nicotinic acid, a fibrate, a HMG CoA reductase inhibitor, a cholesteryl ester transfer protein inhibitor, and combinations thereof.

A novel compound of the formula (I):

wherein R¹ is alkoxycarbonyl or the like, R² is alkyl or the like; R³ is hydrogen or the like; R⁴ is alkylene or the like; R⁵ is optionally substituted heterocyclic group; R⁶, R⁷, and R⁸ are independently hydrogen; alky, alkoxy, or the like; R¹⁰ is optionally substituted aromatic ring, or the like; or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP).

A compound represented by the following general formula (I), wherein R¹, R², R³, R⁴ and R⁵ represent hydrogen atom, a halo(lower alkyl) group, cyano group and the like, R⁶ represents an alkyl group, a cycloalkyl group and the like, R⁷, R⁸, R⁹ and R¹⁰ represent hydrogen atom, a halogen atom, a lower alkyl group, a halo(lower alkyl) group and the like, R¹¹ and R¹² represent hydrogen atom, a lower alkyl group, a (lower cycloalkyl) (lower alkyl) group and the like, and R¹³ represents hydrogen atom, a halogen atom, a lower alkoxy group and the like, which has potent inhibitory activity on cholesterol ester transfer protein (CETP).

A dosage form that includes a cholesteryl ester transfer protein inhibitor in a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release and immediate release of the cholesteryl ester transfer protein inhibitor.

The invention relates to 2,4,5-trisubstituted selenazole compounds and a preparation method, a composition and application thereof, in particular to compounds in a formula (I), or all possible isomers, predrugs, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein each substituent is shown as the description. The invention also relates to a method for preparing the compounds in the formula (I), medicinal compositions comprising the compounds in the formula (I), and application of the compounds in the formula (I) or the medicinal compositions in preparation of medicines for treating and/or preventing phospholipid transfer protein (PLTP) activity increase and/or diseases or syndromes related with the phospholipid transfer protein activity increase. The compounds in the formula (I) have good effect of inhibiting the PLTP activity and/or cholesteryl ester transfer protein (CETP) activity of blood plasma, and can be used for treating diseases on the basis.

This invention relates to inhibitors of CETP and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by CETP.

The invention relates to an immunoenzymatic method for the quantification of protein CETP in plasma, which requires the utilization of fusion protein GST/CETP, the synthetic peptide CETP 11486-S496 and polyclonal antibody anti-CEPT 11486-S496. The method is used in the study of pathologies involving alterations in the CETP levels in plasma or in seric lipids and makes it possible to detect, evaluate and follow-up patients suffering from dyslipidemia and/or risk of altergenesis.